

12

Documentação

- Sobre o autor
- Bibliografia



Sobre o autor

O Dr. Matthias Rath é o médico e cientista mundialmente conhecido, que conduziu uma reveladora investigação relacionada com a prevenção e terapia natural da aterosclerose a principal causa de ataques cardíacos e acidentes vasculares cerebrais. Por esse feito, recebeu a primeira patente do mundo para a reversão natural das doenças cardiovasculares.

Dr. Rath é o fundador da medicina celular, uma inovadora abordagem científica que aponta para que as doenças mais comuns da actualidade, incluindo as doenças cardíacas e o cancro, são a consequência de uma carência prolongada de vitaminas, minerais e outros biocatalisadores do metabolismo dos milhões de células que compõem o nosso corpo.

Os artigos científicos do Dr. Rath foram publicados nas principais revistas científicas, entre elas Arteriosclerosis, da Associação Americana do Coração e Proceedings of the National Academy of Sciences, USA. Os seus livros estão traduzidos em mais de 10 línguas, tendo sido vendidas milhões de cópias em todo o mundo.

Dr. Rath é o fundador e diretor de um instituto internacional de investigação e desenvolvimento, que tem como objectivo a erradicação dos problemas de saúde mais prementes da actualidade, com ajuda da medicina celular e de terapias naturais eficazes e seguras.

As descobertas do Dr. Rath no campo do controle natural eficaz das doenças cardíacas e outras doenças constituem uma ameaça para o negócio multimilionário da indústria farmacêutica, "feito à custa das doenças", que se baseia unicamente em fornecer drogas sintéticas, orientadas exclusivamente para os sintomas. Como consequência directa, as empresas de fármacos deram início a uma campanha internacional para instaurarem "leis protecionistas" para o seu mercado de medicamentos. A sua finalidade é eliminar a informação, valiosa para a vida humana, relacionada com a saúde natural, sacrificando para tal a saúde e a vida humanas.

O site do Dr. Rath é a maior fonte de informação sobre a medicina

celular e saúde natural.



Vou buscar a inspiração para o meu trabalho na natureza. Foi rodeado pelo mundo natural, envolto numa serena solidão, que me ocorreram as reflexões mais criativas.

Bibliografia

A lista bibliográfica que se segue pretende documentar os apoios com que a medicina nutricional e celular contam actualmente. Poderá encontrar estas publicações numa série de bibliotecas públicas, assim como em qualquer biblioteca de escolas de medicina.

- Armstrong VW, Cremer P, Eberle E, et al. (1986) The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL-levels. *Atherosclerosis* 62: 249-257.
- Altschul R, Hoffer A, Stephen JD. (1955) Influence of nicotinic acid on serum cholesterol in man. *Archives of Biochemistry and Biophysics* 54: 558-559.
- Aulinskas TH, Van der Westhuyzen DR, Coetzee GA. (1983) Ascorbate increases the number of low-density lipoprotein receptors in cultured arterial smooth muscle cells. *Atherosclerosis* 47: 159-171.
- Avogaro P, Bon GB, Fusello M. (1983) Effect of pantethine on lipids, lipoproteins and apolipoproteins in man. *Current Therapeutic Research* 33: 488-493.
- Bates CJ, Mandal AR, Cole TJ. (1977) HDL. Cholesterol and vitamin C status. *The Lancet* 31611.
- Beamish R. (1993) Vitamin E - then and now. *Canadian Journal of Cardiology* 9: 29-31.
- Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M. (1990) Lipoprotein (a) in the arterial wall. *European Heart Journal* 11 (Supplement E): 174-183.
- Bendich A. (1992) Safety issues regarding the use of vitamin supplements. *Annals of the New York Academy of Sciences* 669: 300-310.
- Berg K. (1963) A new serum type system in man - the Lp system. *Acta Pathologica Scandinavica* 59: 369-382.
- Blumberg A, Hanck A, Sandner G. (1983) Vitamin nutrition in patients on continuous ambulatory peritoneal dialysis (CAPD). *Clinical Nephrology* 20: 244-250.
- Braunwald E, (Editor) (1992) *Heart Disease-A Textbook of Cardiovascular Medicine*. W.B. Saunders & Company, Philadelphia.
- Briggs M, Briggs M. (1972) Vitamin C requirements and oral contraceptives. *Nature* 238: 277.
- Carlson LA, Hamsten A, Asplund A. (1989). Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. *Journal of Internal Medicine* (England) 226: 271-276.
- Cherchi A, Lai C, Angelino F, Trucco G, Caponnetto S, Mereto PE, Rosolen G, Manzoli U, Schiavoni G, Reale A, Romeo F, Rizzon P, Sorgente I, Strano A,

- Novo S, Immordino R. (1985) *International Journal of Clinical Pharmacology, Therapy and Toxicology*: 569-572.
- Chow CK, Changchit C, Bridges RBI, Rein SR, Humble J, Turk J. (1986) Lower levels of vitamin C and carotenes in plasma of cigarette smokers. *Journal of the American College of Nutrition* 5: 305-312.
- Clemetson CAB. (1989) *Vitamin C, Volume I-III*. CRC Press Inc., Florida.
- Cushing GL, Gaubatz JW, Nave ML, Burdick BJ, Bocan TMA, Guyton JR, Weillbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. (1989) Quantitation and localization of lipoprotein (a) and B in coronary artery bypass vein grafts resected at re-operation. *Arteriosclerosis* 9: 593-603.
- Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM, Jr. (1986) Association of levels of lipoprotein LP(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. *Circulation* 74: 758-765.
- DeMaio SJ, King SB, Lembo NJ, Roubin GS, Hearn JA, Bhagavan HN, Sgoutas DS. (1992) Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). *Journal of the American College of Nutrition* 11: 68-73.
- Dice JF, Daniel CW. (1973) The hypoglycemic effect of ascorbic acid in a juvenile-onset diabetic. *International Research Communications System* 1: 41.
- Digiesi V. (1992) Mechanism of action of coenzyme Q10 in essential hypertension. *Current Therapeutic Research* 51: 668-672.
- Emmert D, Irchner J. (1999) The role of vitamin E in the prevention of heart disease. *Archives of Family Medicine* 8: 537-542.
- England M. (1992) Magnesium administration and dysrhythmias after cardiac surgery: A placebo-controlled, doubleblind randomized trial. *Journal of the American Medical Association* 268: 2395-2402.
- Enstrom JE, Kanim LE, Klein MA. (1992) Vitamin C intake and mortality among a sample of the United States population. *Epidemiology* 3: 194-202.
- Ferrari R, Cucchini, and Visioli O. (1984) The metabolic effects of L-carnitine in angina pectoris. *International Journal of Cardiology* 5: 213-216.
- Folkers K, Yamamura Y (Editors) 1976,1979,1981,1984,1986) *Biomedical and clinical aspects of coenzyme Q*. Volume 1-5. Elsevier Science Publishers, New York.
- Folkers K, Vadhanavikit S, Mortensen SA. (1985) Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. *Proceedings of the National Academy of Sciences, USA* 82: 901-904.

- Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H. (1990) Lovastatin decreases coenzyme Q-10 levels in humans. *Proceedings of the National Academy of Sciences, USA* 87: 8931-8934.
- Gaby SK, Bendich A, Singh VN, Machlin LJ (1991) *Vitamin intake and health*. Marcel Dekker Inc. N.Y.
- Gaddi A, Descovich GC, Nosedà G, Fragiaco C, Colombo L, Craveri A, Montanari G, Sirtori CR. (1984) Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. *Atherosclerosis* 5: 73-83.
- Galeone F, Scalabrino A, Giuntoli F, Birindelli A, Panigada G, Rossi, Saba P. (1983) The lipid-lowering effect of pantethine in hyperlipidemic patients: A clinical investigation. *Current Therapeutic Research* 34: 383-390.
- Genest J Jr., Jenner JL, McNamara JR, Ordovas JM, Silberman SR, Wilson PWF, Schaefer EJ. (1991) Prevalence of lipoprotein (a) Lp(a) excess in coronary artery disease. *American Journal of Cardiology* 67: 1039-1045.
- Gerster H. (1991) Potential role of beta-carotene in the prevention of cardiovascular disease. *International Journal of Vitamin and Nutrition Research* 61: 277-291.
- Gey KF, Stähelin HB, Puska P and Evans A. (1987) Relationship of plasma level of vitamin C to mortality from ischemic heart disease. 110-123. In: Burns JJ, Rivers JM, Machlin LJ (Editors): Third conference on vitamin C. *Annals of the New York Academy of Sciences* 498.
- Gey KF, Puska P, Jordan P, Moser UK. (1991) Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. *American Journal of Clinical Nutrition* 53: 326, Supplement.
- Ghidini O, Azzurro M, Vita A, Sartori G. (1988) Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure. *International Journal of Clinical Pharmacology, Therapy and Toxicology* 26: 217-220.
- Ginter E. (1973) Cholesterol: Vitamin C controls its transformation into bile acids. *Science* 179: 702.
- Ginter E. (1978) Marginal vitamin C deficiency, lipid metabolism, and atherosclerosis. *Lipid Research* 16: 216-220.
- Ginter E. (1991) Vitamin C deficiency, cholesterol metabolism, and atherosclerosis. *Journal of Orthomolecular Medicine* 6: 166-173.
- Guraker A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. (1985) Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. *Atherosclerosis* 57: 293-301.
- Halliwell B, Gutteridge JMC (1985) *Free radicals in biology and medicine*. Oxford University Press, London, New York, Toronto.

- Harwood HJ Jr, Greene YJ, Stacpoole PW (1986) Inhibition of human leucocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by ascorbic acid. An effect mediated by the free radical monodehydro-ascorbate. *Journal of Biological Chemistry* 261: 7127-7135.
- Hearn JA, Donohue BC, Ba'albaki H, Douglas JS, King SBIII, Lembo NJ, Roubin JS, Sgoutas DS. (1992) Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. *The American Journal of Cardiology* 68: 736-739.
- Hennekens, C. See: Rimm EB (1993) and Stampfer (1993). Hermann WJ JR, Ward K, Faucett J. (1979) The effect of tocopherol on high-density lipoprotein cholesterol. *American Journal of Clinical Pathology* 72: 848-852.
- Hemilä H. (1992) Vitamin C and plasma cholesterol. In: *Critical Reviews in Food Science and Nutrition* 32 (1): 33-57, CRC Press Inc., Florida.
- Hodis H, Azen S, Qian D, et. al. (1996) Effect of Supplementary Antioxidant Vitamin Intake on Carotid Arterial Wall Intima-Media Thickness in a Controlled Clinical Trial of Cholesterol Lowering. *Circulation* 94(10): 2369-72.
- Hoff HF, Beck GJ, Skibinski CI, Jürgens G, O'Neil J, Kramer J, Lytle B. (1988) Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. *Circulation* 77: 1238-1244.
- Iseri LT. (1986) Magnesium and cardiac arrhythmias. *Magnesium* 5: 111-126.
- Iseri LT, French JH. (1984) Magnesium: Nature's physiologic calcium blocker. *American Heart Journal* 108: 188-193.
- Jacques PF, Hartz SC, McGandy RB, Jacob RA, Russell RM. (1987) Ascorbic acid, HDL, and total plasma cholesterol in the elderly. *Journal of the American College of Nutrition* 6: 169-174.
- Kamikawa T, Kobayashi A, Emaciate T, Hayashi H, Yamazaki N. (1985) Effects of coenzyme Q-10 on exercise tolerance in chronic stable angina pectoris. *American Journal of Cardiology* 56: 247-251.
- Koh ET (1984) Effect of Vitamin C on blood parameters of hypertensive subjects. *Oklahoma State Medical Association Journal* 77: 177-182.
- Korbut R. (1993) Effect of L-arginine on plasminogen-activator inhibitor in hypertensive patients with hypercholesterolemia. *New England Journal of Medicine* 328 [4]:287-288.
- Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. (1981) Lipoprotein Lp(a) and the risk for myocardial infarction. *Atherosclerosis* 38: 51-61.

- Kurl S, Tuomainen TP, Laukkanen JA, et. al. (2002) Plasma vitamin C modifies the association between hypertension and risk of stroke. *Stroke* 33 (6):1568-73.
- Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. (1988) Effective and safe therapy with coenzyme Q10 for cardiomyopathy. *Klinische Wochenschrift* 66: 583-590.
- Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. (1990) Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. *International Journal of Tissue Reactions XIII* (3) 163-168.
- Lavie CJ. (1992) Marked benefit with sustained-release niacin (vitamin B3) therapy in patients with isolated very low levels of high-density lipoprotein cholesterol and coronary artery disease. *The American Journal of Cardiology* 69: 1093-1085.
- Lawn RM. (1992) Lipoprotein (a) in heart disease. *Scientific American*. June: 54-60.
- Lehr, HA, Frei B, Arfors KE. (1994) Vitamin C prevents cigarette smoke-induced leucocyte aggregation and adhesion to endothelium in vivo. *Proceedings of the National Academy of Sciences* 91: 7688-7692.
- Levine M. (1986) New concepts in the biology and biochemistry of ascorbic acid. *New England Journal of Medicine* 314: 892-902.
- Liu VJ, Abernathy RP. (1982) Chromium and insulin in young subjects with normal glucose tolerance. *American Journal of Clinical Nutrition* 25: 661-667.
- Maeda N, et. al. (2000) Aortic wall damage in mice unable to synthesize ascorbic acid. *Proceedings of the National Academy of Sciences USA* 97(2): 841-846
- Mann GV, Newton P. (1975) The membrane transport of ascorbic acid. Second Conference on Vitamin C. 243-252. *Annals of the New York Academy of Sciences*.
- Mather HM, et al. (1979) Hypomagnesemia in diabetes. *Clinical and Chemical Acta* 95: 235-242.
- McBride PE and Davis JE. (1992) Cholesterol and cost-effectiveness implications for practice, policy, and research. *Circulation* 85: 1939-1941.
- McCarron DA, Morris CD, Henry HJ and Stanton JL. (1984) Blood pressure and nutrient intake in the United States. *Science* 224: 1392-1398.
- McNair P, et al. (1978) Hypomagnesemia, a risk factor in diabetic retinopathy. *Diabetes* 27: 1075-1077.
- Miccoli R, Marchetti P, Sampietro T, Benzi L, Tognarelli M, Navalesi R. (1984) Effects of pantethine on lipids and apolipoproteins in hypercholesterolemic

- diabetic and nondiabetic patients. *Current Therapeutic Research* 36: 545-549.
- Mikami H, et al. (1990) Blood pressure response to dietary calcium intervention in humans. *American Journal of Hypertension* 3: 147-151.
- Moore TJ. (1995) *Deadly Medicine*.: Simon & Schuster, New York.
- Newman TB and Hulley SB. (1996) Carcinogenicity of lipidlowering drugs. *Journal of the American Medical Association* 275: 55-60.
- Niedzwiecki A, Ivanov V. (1994) Direct and extracellular matrix mediated effect of ascorbate on vascular smooth muscle cell proliferation. 24th AAA (Age) and 9th American College of Clinical Gerontology Meeting Washington D.C. Niendorf A, Rath M, Wolf K, Peters S, Arps H, Beisiegel U, Dietel M. (1990) Morphological detection and quantification of lipoprotein (a) deposition in atheromatous lesions of human aorta and coronary arteries. *Virchow's Archives of Pathological Anatomy* 417: 105-111.
- Nunes GL, Sgoutas DS, Redden RA, Sigman SR, Gravanis MB, King SB, Berk BC. (1995) Combination of Vitamin C and E alters the response to coronary balloon injury in the pig. *Arteriosclerosis, Thrombosis and Vascular Biology* 15: 156-165.
- Opie LH. (1979) Review: Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. *American Heart Journal* 97: 375-388.
- Paolisso G, et al. (1993) Pharmacologic doses of vitamin E improve insulin action in healthy subjects and in noninsulin-dependent diabetic patients. *American Journal of Clinical Nutrition* 57: 650-656.
- Paterson JC. (1941) *Canadian Medical Association Journal* 44: 114-120. Some factors in the causation of intimal hemorrhages and in the precipitation of coronary thrombi.
- Pauling L. (1986) *How to Live Longer and Feel Better*. WH Freeman and Company, New York.
- Pfleger R, Scholl F. (1937) Diabetes und vitamin C. *Wiener Archiv für Innere Medizin* 31: 219-230.
- Psaty BM, Heckbert SR, Koepsell TD, et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. *Journal of the American Medical Association* 274: 620-625.
- Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. (1989) Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. *Arteriosclerosis* 9: 579-592.
- Rath M, Pauling L. (1990a) Hypothesis: Lipoprotein (a) is a surrogate for ascorbate. *Proceedings of the National Academy of Sciences USA* 87: 6204-6207.

- Rath M, Pauling L (1990b) Immunological evidence for the accumulation of lipoprotein (a) in the atherosclerotic lesion of the hypoascorbemic guinea pig. *Proceedings of the National Academy of Sciences USA* 87: 9388-9390.
- Rath M, Pauling L. (1991a) Solution to the puzzle of human cardiovascular disease: Its primary cause is ascorbate deficiency, leading to the deposition of lipoprotein (a) and fibrinogen/ fibrin in the vascular wall. *Journal of Orthomolecular Medicine* 6: 125-134.
- Rath M, Pauling L. (1991b) Apoprotein(a) is an adhesive protein. *Journal of Orthomolecular Medicine* 6: 139-143.
- Rath M., Pauling L. (1992a) A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. *Journal of Orthomolecular Medicine* 7: 5-15.
- Rath M, Pauling L. (1992b) Plasmin-induced proteolysis and the role of apoprotein(a), lysine, and synthetic lysine analogs. *Journal of Orthomolecular Medicine* 7: 17-23.
- Rath M. (1992c) Lipoprotein-a reduction by ascorbate. *Journal of Orthomolecular Medicine* 7: 81-82.
- Rath M. (1992d) Solution to the puzzle of human evolution. *Journal of Orthomolecular Medicine* 7: 73-80.
- Rath M. (1992e) Reducing the risk for cardiovascular disease with nutritional supplements. *Journal of Orthomolecular Medicine* 7: 153-162.
- Rath M. (1993c) A new era in medicine. *Journal of Orthomolecular Medicine* 8: 134-135.
- Rath M. (1996) The Process of Eradicating Heart Disease Has Become Irreversible. *Journal of Applied Nutrition* 48: 22-33.
- Rath M., Niedzwiecki A. (1996) Nutritional Supplement Program Halts Progression of Early Coronary Atherosclerosis Documented by Ultrafast Computed Tomography. *Journal of Applied Nutrition*. 48: 68-78.
- Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. (1986) Lp(a) Lipoprotein as a risk factor for myocardial infarction. *Journal of the American Medical Association* 256: 2540-2544.
- Riales RR, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. *American Journal of Clinical Nutrition* 34: 2670-2678.
- Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. (1991) Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. *The Lancet* 337: 1-5.

- Rimm EB, Stampfer MJ, Ascherio AA, Giovannucci E, Colditz GA, Willett WC. (1993) Vitamin E consumption and the risk of coronary heart disease in men. *New England Journal of Medicine* 328: 1450-1449.
- Rivers JM. (1975) Oral contraceptives and ascorbic acid. *American Journal of Clinical Nutrition* 28: 550-554.
- Rizzon P, Biasco G, Di Biase M, Boscia F, Rizzo U, Minafra F, Bortone A, Silprandi N, Procopio A, Bagiella E, Corsi M. (1989) High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. *European Heart Journal* 10: 502-508.
- Robinson K, Arheart K, Refsum H, et. al. (1998) Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. *Circulation* 97(5):437-43. Erratum in: *Circulation* (1999) 99(7): 983.
- Rudolph Willi (1939) *Vitamin C und Ernährung*. Enke Verlag Stuttgart.
- Salonen JT, Salonen R, Ihanainen M, Parviainen M, Seppänen R, Seppänen K, Rauramaa R. (1987) Vitamin C deficiency and low linolenate intake associated with elevated blood pressure: The Kuopio Ischemic Heart Disease Risk Factor Study. *Journal of Hypertension* 5 (Supplement 5): S521-S524.
- Salonen JT, Salonen R, Seppänen K, Rinta-Kiikka S, Kuukka M, Korpela H, Alfthan G, Kantola M, Schalch W. (1991) Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, doubleblind trial in men with low antioxidant status. *American Journal of Clinical Nutrition* 53: 1222-1229.
- Sauberlich HE, Machlin LJ (Editors). (1992) Beyond deficiency: New views on the function and health effects of vitamins. *Annals of the New York Academy of Sciences* v. 669.
- Shimon I, Almog S, Vered Z, et.al. (1995) Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. *American Journal of Medicine* 98: 5 485-90.
- Smith HA, Jones TC. (1958). *Veterinary Pathology*.
- Sokoloff B, Hori M, Saelhof CC, Wrzolek T, Imai T. (1966) Aging, atherosclerosis and ascorbic acid metabolism. *Journal of the American Gerontology Society* 14: 1239-1260.
- Som S, Basu S, Mukherjee D, Deb S, Choudhury PR, Mukherjee S, Chatterjee SN, Chatterjee IB. (1981) Ascorbic acid metabolism in diabetes mellitus. *Metabolism* 30: 572-577.
- Spittle CR (1971) Atherosclerosis and Vitamin C. *Lancet* 2:1280-1.


- Stampfer MJ, Hennekens CH, et al. (1993) Vitamin E consumption and the risk of coronary disease in women. *New England Journal of Medicine* 328(20):1444-9.
- Stankova L, Riddle M, Larned J, Burry K, Menashe D, Hart J, Bigley R. (1984) Plasma ascorbate concentrations and blood cell dehydroascorbate transport in patients with diabetes mellitus. *Metabolism* 33: 347-353.
- Stephens NG, Parsons A, Schofield PM, et al. (1996) Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 347: 781-6.
- Stepp W, Schroeder H, Altenburger E. (1935) Vitamin C und Blutzucker. *Klinische Wochenschrift* 14 [26]: 933-934.
- Stryer L. (1988) *Biochemistry*. 3rd edition. W.H. Freeman and Company New York.
- Tarry WC. (1994) L-arginine improves endothelium-dependent vasorelaxation and reduces initial hyperplasia after balloon angioplasty. *Arteriosclerosis and Thrombosis* 14: 938-943.
- Teo KK, Salim Y. (1993) Role of magnesium in reducing mortality in acute myocardial infarction: *A review of the evidence*. *Drugs* 46[3]: 347-359.
- Thomsen JH, Shug AL, Yap VU, et al. Improved pacing tolerance of the ischemic human myocardium after administration of carnitine. *American Journal of Cardiology* 43: 300-306.
- Toufexis A. (1992) The New Scoop on Vitamins. *Time Magazine* 1139(14): 54-59.
- Turlapaty P, Altura BM. (1980) Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease. *Science* 208: 198-200.
- Virchow R. (1859) *Cellular Pathologie*. Berlin: August Hirschwald.
- Vital Statistics of the United States, US Department of Health and Human Services, National Center for Health Statistics, 1994.
- Widman L, et al. (1993) The dose-dependent reduction in blood pressure through administration of magnesium. A double blind placebo-controlled cross-over study. *American Journal of Hypertension* 6(1):161-165
- Willis GC, Light AW, Gow WS. (1954) Serial arteriography in atherosclerosis. *Canadian Medical Association Journal* 71:562-568.
- World Health Statistics, World Health Organization, Geneva, 1994.
- Yokoyama T, Date C, Kokubo Y, et al. (2000) Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata Study. *Stroke* 31(10): 2287-94.
- Zenker G, Koeltringer P, Bone G, Kiederhorn K, Pfeiffer K, Jürgens G. (1986) Lipoprotein (a) as a Strong Indicator for Cardiovascular Disease. *Stroke* 17: 942-945.

Outras fontes úteis

CHE

Livros interativos para aprender

Imagens deste livro vêm dos aplicativos CHE



CHE é uma série de livros interativos, que fornece um conhecimento geral sobre a saúde e doenças. Através deste caminho a saúde será para todas pessoas desta terra possível

CHE está disponível como download gratuito



Por exemplo,
CHE Cardiovascular System
disponível gratuitamente

Investigação inovadora de micronutrientes no Dr. Rath Instituto de Pesquisa

O Dr. Rath Instituto de Pesquisa em Santa Clara, na Califórnia é uma das principais instituições de pesquisa do mundo na área de terapias naturais com base científica.

Pesquisa sobre as sinergias de micronutrientes

Além do trabalho de pesquisa com componentes naturais individuais, tais como vitaminas, aminoácidos ou várias substâncias vegetais, é examinado a sinérgica interação desses micronutrientes na luta contra várias doenças.


Na área das doenças cardiovasculares tem a equipe de pesquisa, dirigida pela Dr. Aleksandra Niedzwiecki, o seguinte foco: aterosclerose como a doença básica do infarto do miocárdio e ataque vascular cerebral (AVC), insuficiência cardíaca, hipertensão e arritmias cardíacas. Além da pesquisa cardiovascular, a pesquisa de cancro é outro foco especial.

Pesquisa sem fins lucrativos

O nosso instituto de pesquisa funciona sob um telhado sem fins lucrativos, isto é, a pesquisa não está alinhada em objetivos comerciais e lucro. O motivo principal de nossa pesquisa é apenas a exclusiva importância como causa de doença e morte prematura de milhões de pessoas. O instituto é apoiado principalmente por pessoas que já beneficiaram destes resultados de pesquisa.



Os resultados da pesquisa do instituto estão acessíveis para todas as pessoas e podem ser encontradas através do site do instituto ou através de Pubmed.

www.drrathresearch.org



O avanço para o controle natural da doença cardiovascular

- Aprofundamento do conteúdo deste livro na palestra (engl.)
- A palestra mundialmente mais assistida aos novos conhecimentos sobre o desenvolvimento de doenças cardíacas
- Mais de 200.000 visualizações no Youtube



<https://www.youtube.com/watch?v=O0lEmXJD7p4>